214 related articles for article (PubMed ID: 32012941)
1. Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach.
Grigorieva J; Asmellash S; Net L; Tsypin M; Roder H; Roder J
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012941
[TBL] [Abstract][Full Text] [Related]
2. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy.
Park Y; Kim MJ; Choi Y; Kim NH; Kim L; Hong SPD; Cho HG; Yu E; Chae YK
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347071
[TBL] [Abstract][Full Text] [Related]
5. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
10. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
12. Spatiotemporal Changes in Checkpoint Molecule Expression.
Li W; Qie J; Zhang Y; Chang J
Adv Exp Med Biol; 2020; 1248():167-200. PubMed ID: 32185711
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients.
Sun J; Li X; Wang Q; Chen P; Zhao L; Gao Y
Front Pharmacol; 2024; 15():1349459. PubMed ID: 38881867
[No Abstract] [Full Text] [Related]
15. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
16. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
17. Possible Biomarkers for Cancer Immunotherapy.
Otoshi T; Nagano T; Tachihara M; Nishimura Y
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277279
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
19. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
20. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
Chen JA; Ma W; Yuan J; Li T
Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
